DNASENSE ApS: Financial statements 2023
CVR: 36036869
Source: annual report 2023, Danish Business Authority
01/10/2022 – 30/09/2023
DNASENSE ApS (CVR 36036869) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 4,532,635 and a net result of DKK 549,847 compared with DKK 866,938 the year before. That is an increase of 6.4% compared with the year before. Equity in the 2023 report amounted to DKK 801,815. The solvency ratio was 36.1%. The company had 7 employees in the financial year.
- Gross Profit
- DKK 4,532,635
- Profit/Loss
- DKK 549,847
- Equity
- DKK 801,815
- Total Assets
- DKK 2,219,254
- Employees
- 7
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 4.5 mio. | 550 t. | 802 t. | 7 |
| 2022 | - | 4.3 mio. | 867 t. | 852 t. | 6 |
| 2021 | - | 3 mio. | 78 t. | -15 t. | 5 |
| 2020 | - | 1.4 mio. | -1.1 mio. | -93 t. | 5 |
| 2019 | - | 3.4 mio. | 679 t. | 1.3 mio. | 4 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
DNASENSE ApS has published its annual report for 2022. Gross profit came to DKK 4,258,224, and the net result was DKK 866,938.
About DNASENSE ApS
DNASENSE ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2014. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Mads Toft Søndergaard. The board consists of Anders Christian Neto de Sousa Grøn (chair), Anders Mohr Christensen, Henrik Bjørn Nielsen and Manoj Nirmal Dadlani. The company is owned by Clinical-Microbiomics A/S. The company has 15 employees (2018). In 2025, the company reported a gross profit of DKK 7,915,337 and a net result of DKK 894,729. Equity in the 2025 report amounted to DKK 1,639,012.